ESMO 2017: 3-week dosing schedule for paclitaxel is suitable as first-line treatment for European women with ovarian cancer


  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Caucasian women with ovarian cancer can be treated with the standard 3-week dosing schedule for paclitaxel according to ICON8 phase 3 study presented at ESMO 2017.

Why this matters

  • The study, conducted by the MRC Clinical Trials Unit at UCL, contradicts the results of the J...